What was the most significant event for Cencora (AmerisourceBergen) in fiscal year 2001?

The most significant event was the merger between AmeriSource Health Corporation and Bergen Brunswig Corporation, which was completed on August 29, 2001. This merger created AmerisourceBergen Corporation, a leading pharmaceutical services company in the United States.

What are the main business segments of AmerisourceBergen?

AmerisourceBergen operates in two primary segments: Pharmaceutical Distribution, which includes wholesale and specialty drug distribution, and PharMerica, which provides institutional pharmacy services to long-term care and alternate site settings.

What are the key strategies the company is employing for future growth?

The company's strategy includes continuing growth in existing markets by offering superior distribution services and value-added solutions, expanding growth through healthcare solutions for customers and suppliers, and improving operating and capital efficiencies through integration and technology investments.

What is the company's approach to managing its debt and capital resources?

Following the merger, the company established significant new debt facilities, including senior notes and a large credit facility, to support operations and integration. They also utilize receivables securitization financing. The company's cash flow generation, combined with debt financing, is expected to meet its ongoing capital requirements, including working capital and integration initiatives.

COR 10-K FY2001 Annual Report — Revenue, Net Income, EPS

Summary

This 10-K filing for Cencora, Inc. (formerly AmerisourceBergen Corporation) for the fiscal year ended September 29, 2001, details the significant merger between AmeriSource Health Corporation and Bergen Brunswig Corporation, creating a leading pharmaceutical services company in the United States. The company operates primarily in two segments: Pharmaceutical Distribution and PharMerica (institutional pharmacy services). The filing highlights the strategic advantages of the merger, including expanded scale, broader service offerings, and opportunities for operational efficiencies. Despite significant merger-related costs and integration efforts, the combined entity is positioned to capitalize on industry growth drivers such as an aging population, new pharmaceutical development, and the increasing use of outpatient drug therapies. Investors should note the company's focus on value-added solutions for both customers and suppliers, a commitment to improving operating efficiencies, and a decentralized operating structure designed for rapid customer response.

Key Highlights

1Formation of AmerisourceBergen Corporation through the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in August 2001, creating the largest U.S. pharmaceutical services company solely dedicated to the pharmaceutical supply chain.
2The company operates in two main segments: Pharmaceutical Distribution (wholesale and specialty drug distribution) and PharMerica (institutional pharmacy services).
3A key business strategy is to drive growth through existing markets and by expanding healthcare solutions for both customers and suppliers.
4Significant investments in advanced management information systems and warehouse automation are underway to improve efficiency and customer service.
5The company is actively pursuing merger integration plans to consolidate its distribution network, aiming for approximately $150 million in annual synergies.
6The filing details the company's debt structure, including new senior notes and a significant credit facility established post-merger, to support operations and integration.
7AmerisourceBergen faces competition from national players like Cardinal Health and McKesson Corporation, as well as regional and local distributors.

Cencora, Inc. Annual Report, Year Ended Sep 30, 2001

Summary

Key Highlights

Frequently Asked Questions